# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Longeveron (NASDAQ:LGVN) with a Buy and maintains $12 price ta...
Longeveron (NASDAQ:LGVN) reported quarterly losses of $(1.61) per share which beat the analyst consensus estimate of $(2.00) by...
https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11975068
https://t.co/L1bepDtcf3
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Longeveron (NASDAQ:LGVN) with a Buy, adjusts target to $12 from...
Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developin...
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Wednesday. The D...
Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings.